Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages - Institut Pasteur Accéder directement au contenu
Article Dans Une Revue iScience Année : 2023

Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages

Franck Touret
  • Fonction : Auteur correspondant
  • PersonId : 1066975

Connectez-vous pour contacter l'auteur

Résumé

The landscape of SARS-CoV-2 variants dramatically diversified with the simultaneous appearance of multiple subvariants originating from BA.2, BA.4, and BA.5 Omicron sub-lineages. They harbor a specific set of mutations in the spike that can make them more evasive to therapeutic monoclonal antibodies. In this study, we compared the neutralizing potential of monoclonal antibodies against the Omicron BA.2.75.2, BQ.1, BQ.1.1, and XBB variants, with a pre-Omicron Delta variant as a reference. Sotrovimab retains some activity against BA.2.75.2, BQ.1, and XBB as it did against BA.2/BA.5, but is less active against BQ.1.1. Within the Evusheld/AZD7442 cocktail, Cilgavimab lost all activity against all subvariants studied, resulting in loss of Evusheld activity. Finally, Bebtelovimab, while still active against BA.2.75, also lost all neutralizing activity against BQ.1, BQ.1.1, and XBB variants.
Fichier principal
Vignette du fichier
1-s2.0-S258900422300490X-main.pdf (1.33 Mo) Télécharger le fichier
Origine : Publication financée par une institution
Licence : CC BY NC ND - Paternité - Pas d'utilisation commerciale - Pas de modification

Dates et versions

pasteur-04072734 , version 1 (18-04-2023)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

Citer

Franck Touret, Emilie Giraud, Jérôme Bourret, Flora Donati, Jaouen Tran-Rajau, et al.. Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages. iScience, 2023, 26 (4), pp.106413. ⟨10.1016/j.isci.2023.106413⟩. ⟨pasteur-04072734⟩
147 Consultations
45 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More